Abstract
To summarize the influence of pre-existing diabetes on mortality and morbidity in men with prostate cancer. We searched MEDLINE and EMBASE from inception through 1 October 2008. Search terms were related to diabetes, cancer and prognosis. Studies were included if they reported an original data analysis of prostate cancer prognosis, compared outcomes between men with and without diabetes and were in English. Titles, abstracts and articles were reviewed independently by two authors. Conflicts were settled by consensus or third review. We abstracted data on study design, analytic methods, outcomes and quality. We summarized mortality and morbidity outcomes qualitatively and conducted a preliminary meta-analysis to quantify the risk of long-term (>3 months), overall mortality. In total, 11 articles were included in the review. Overall, one of four studies found increased prostate cancer mortality, one of two studies found increased nonprostate cancer mortality and one study found increased 30-day mortality. Data from four studies could be included in a preliminary meta-analysis for long-term, overall mortality and produced a pooled hazard ratio of 1.57 (95% CI: 1.12–2.20). Diabetes was also associated with receiving radiation therapy, complication rates, recurrence and treatment failure. Our analysis suggests that pre-existing diabetes affects the treatment and outcomes of men with prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Cancer Society. Cancer Facts & Figures 2009. American Cancer Society: Atlanta, GA, USA, 2009.
National Cancer Institute. Cancer stat fact sheets: cancer of the prostate. Available at: http://seer.cancer.gov/statfacts/html/prost.html?statfacts_page=prost.html&x=13&y=16.
Anderson G, Horvath J . Chronic Conditions: Making the Case for Ongoing Care. Robert Wood Johnson Foundation's Partnership for Solutions: Princeton, NJ, USA, 2002.
Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2008.
Selvin E, Coresh J, Brancati FL . The burden and treatment of diabetes in elderly individuals in the US. Diabetes Care 2006; 29: 2415–2419.
Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL et al. Increased long-term, all-cause mortality in cancer patients with pre-existing diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754–2764.
Kasper JS, Giovannucci E . A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056–2062.
Duval S, Tweedie R . Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455–463.
Chan JM, Latini DM, Cowan J, DuChane J, Carroll PR . History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE. Cancer Causes Control 2005; 16: 789–797.
Fleming ST, Pearce KA, McDavid K, Pavlov D . The development and validation of a comorbidity index for prostate cancer among Black men. J Clin Epidemiol 2003; 56: 1064–1075.
Froehner M, Koch R, Litz R, Oehlschlaeger S, Noacks B, Manseck A et al. Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology 2003; 61: 596–600.
Hammarsten J, Hogstedt B . Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887–2895.
Herold DM, Hanlon AL, Hanks GE . Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 1999; 43: 475–479.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E . The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naïve Gleason score 7 prostate cancer. Cancer J 2005; 11: 234–240.
Merrick GS, Galbreath RW, Butler WM, Waller KE, Allen ZA, Lief J et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer 2007; 110: 289–296.
Park SM, Lim MK, Shin SA, Yun YH . Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 2006; 24: 5017–5024.
Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol 2008; 26: 4333–4339.
van de Poll-Franse LV, Houterman S, Janssen-Heijnen MLG, Dercksen MW, Coebergh JWW, Haak HR . Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 2007; 120: 1986–1992.
Wilt TJ, Cowper DC, Gammack JK, Going DR, Nugent S, Borowsky SJ . An evaluation of radical prostatectomy at Veterans Affairs medical centers: time trends and geographic variation in utilization and outcomes. Med Care 1999; 37: 1046–1056.
Peehl DM, Stamey TA . Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol 1986; 22: 82–90.
Sarma AV, Jaffe CA, Schottenfeld D, Dunn R, Montie JE, Cooney KA et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology 2002; 59: 362–367.
Pollak M, Beamer W, Zhang JC . Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998–1999; 17: 383–390.
Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X . The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008; 13: 3273–3287.
Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD et al. Delayed activation of insulin-like growth factor1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 2005; 280: 14212–14221.
Loboda A, Jazwa A, Grochot-Przeczek A, Rutkowski AJ, Cisowski J, Agarwal A et al. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2008; 10: 1767–1812.
Acknowledgements
Dr Snyder is supported by a Mentored Research Scholar Grant from the American Cancer Society (MRSG-08-011-01-CPPB). Ms Barone and Dr Derr are supported by the NIDDK Diabetes and Obesity Training Grant (T32 DK062707). Dr Stein is supported by a NIH fellowship from Health Services and Administration (T32HP10025-14). Dr Brancati is supported by the NIDDK Patient Oriented Research in Type 2 Diabetes Grants (K24-DK62222). Drs Yeh and Brancati are supported by the NIDDK Diabetes Research and Training Center (P60 DK079637). No funding body had a role in study design, data collection, analysis or reporting.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Snyder, C., Stein, K., Barone, B. et al. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 13, 58–64 (2010). https://doi.org/10.1038/pcan.2009.39
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2009.39
Keywords
This article is cited by
-
Adipocytes protect fibroblasts from radiation-induced damage by adiponectin secretion
Scientific Reports (2020)
-
Trends in cancer mortality among people with vs without diabetes in the USA, 1988–2015
Diabetologia (2020)
-
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Nature Reviews Clinical Oncology (2017)
-
Outcomes of preexisting diabetes mellitus in breast, colorectal, and prostate cancer
Journal of Cancer Survivorship (2017)
-
Diabetes and mortality in patients with prostate cancer: a meta-analysis
SpringerPlus (2016)